Several other analysts also recently commented on the stock. Maxim Group reaffirmed a buy rating and set a $16.00 target price on shares of Mesoblast in a report on Thursday, September 12th. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the stock a buy rating in a report on Tuesday, September 10th. Oppenheimer set a $10.00 target price on shares of Mesoblast and gave the stock a buy rating in a report on Tuesday, September 10th. Chardan Capital set a $6.00 target price on shares of Mesoblast and gave the stock a hold rating in a report on Friday, August 30th. Finally, Zacks Investment Research downgraded shares of Mesoblast from a buy rating to a hold rating in a report on Friday, September 6th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Mesoblast has a consensus rating of Buy and an average price target of $11.67.
Shares of MESO stock opened at $7.10 on Monday. The company has a market capitalization of $668.61 million, a price-to-earnings ratio of -7.80 and a beta of 1.77. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.41 and a current ratio of 1.41. The company has a 50-day simple moving average of $5.29 and a 200 day simple moving average of $5.17. Mesoblast has a 52 week low of $3.35 and a 52 week high of $8.78.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley boosted its holdings in Mesoblast limited (NASDAQ:MESO) by 284.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the quarter. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Recommended Story: Technical Analysis of Stocks and What It Means
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.